Danish Study Investigates GLP-1 Agonist Safety Around Conception and Pregnancy Outcomes
Background
GLP-1 receptor agonists (GLP-1 RAs) like semaglutide and liraglutide are increasingly prescribed for managing type 2 diabetes and obesity. These medications are typically not recommended during pregnancy due to limited human data on fetal safety and potential adverse effects. This creates a critical knowledge gap regarding the real-world impact of early exposure. This study addresses the impact of periconceptional GLP-1 RA exposure on various obstetric outcomes in a large population.
Results
The study found no statistically significant increase in the risk of major congenital malformations among infants exposed to GLP-1 receptor agonists periconceptionally (adjusted odds ratio [aOR] 1.05, 95% CI 0.88-1.25, p=0.58). The most important finding was that the overall rate of major birth defects in the exposed group was 3.2%, which was comparable to the 3.0% observed in the unexposed group (aOR 1.07, 95% CI 0.90-1.27, p=0.43). However, a slight, non-significant increase in preterm birth was noted in the exposed group (11.5% vs 9.8% in controls, aOR 1.18, 95% CI 0.99-1.40, p=0.06). No significant associations were found for small for gestational age or preeclampsia.
Why It Matters
This large-scale, real-world data provides crucial insights into the safety profile of GLP-1 receptor agonists when exposure occurs around conception. The reassurance regarding major congenital malformations is particularly important for patients and clinicians, potentially alleviating concerns for those who may have inadvertently been exposed. These findings can help inform clinical guidelines and patient counseling for women of reproductive age using these medications, especially when considering family planning. Further research, potentially through prospective registries or Phase IV studies, is warranted to confirm these findings and explore other potential long-term outcomes.